Aducanumab: an uprising hope with vague horizons

Abstract Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Amyloid-beta (Aβ) deposition, one processes involved in pathophysiology AD, has inspired interest targeted therapies, including monoclonal antibodies. Aducanumab acts as a fully human IgG1 antibody against Aβ by binding to amyloid plaques and was approved Food Drug Administration (FDA) first disease-modifying drug for mild cognitive impairment stages AD. This accelerated approval, albeit termination two phase III clinical trials aducanumab due results futility analysis, provoked controversy among key opinion leaders field neurology. poses significant financial constraints on patients healthcare systems. Furthermore, precise diagnosis AD appropriate initiation remains formidable challenge. The drug’s administration necessitates specialized infrastructure medical equipment, it may induce amyloid-related imaging abnormalities (ARIA), potentially resulting cerebral edema or hemorrhage. These disadvantages might outweigh potential benefits medication, especially considering uncertainties regarding its efficacy. commentary intended briefly evaluate application developing countries, associated diagnostic challenges, efficacy, cost, adverse effects.